ARTICLE | Tools & Techniques
Getting Euroclidian on GPCRs
December 22, 2003 8:00 AM UTC
The acquisition of GPCR service company Euroclide SA will give Faust Pharmaceuticals S.A. another tool with which to identify leads for neurodegenerative diseases. Although Euroclide had only five employees, just two of whom are joining Faust, the company held intellectual property and know-how for two techniques for identifying ligands to GPCRs.
Euroclide's technology also is complementary to Faust's own in vitro technology, which allows quantification of the levels of all the major neurotransmitters in the synaptic cleft (see BioCentury, Sept. 8). ...